相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cytotoxic CD8+T cells in cancer and cancer immunotherapy
Hans Raskov et al.
BRITISH JOURNAL OF CANCER (2021)
Cancer immunotherapy harnessing γδ T cells and programmed death-1
Yoshimasa Tanaka
IMMUNOLOGICAL REVIEWS (2020)
CD8+ T cell states in human cancer: insights from single-cell analysis
Anne M. Van der Leun et al.
NATURE REVIEWS CANCER (2020)
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
Bagher Farhood et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer
Bruno Silva-Santos et al.
NATURE REVIEWS CANCER (2019)
PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
Yuan Li et al.
BMC CANCER (2018)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Unconventional T Cell Targets for Cancer Immunotherapy
Dale I. Godfrey et al.
IMMUNITY (2018)
Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy
Wenquan Ou et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy
Adriana Albini et al.
FRONTIERS IN IMMUNOLOGY (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
Ashley M. Hopkins et al.
BRITISH JOURNAL OF CANCER (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials
Heleen. H. Van Acker et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer
Vianey Gonzalez-Villasana et al.
CLINICAL CANCER RESEARCH (2015)
Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group
Haruyasu Murakami et al.
CANCER SCIENCE (2014)
Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study
G. V. Scagliotti et al.
ANNALS OF ONCOLOGY (2012)
Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice
Penelope D. Ottewell et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases
B. Beuselinck et al.
BRITISH JOURNAL OF CANCER (2012)
Cancer-Induced Immunosuppression: IL-18-Elicited Immunoablative NK Cells
Magali Terme et al.
CANCER RESEARCH (2012)
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma
Daniel Keizman et al.
EUROPEAN JOURNAL OF CANCER (2012)
Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens
Masashi Iwasaki et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Interleukin-18: Biology and Role in the Immunotherapy of Cancer
S. Srivastava et al.
CURRENT MEDICINAL CHEMISTRY (2010)
Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer
Kishan J. Pandya et al.
LUNG CANCER (2010)
How Do Bisphosphonates Inhibit Bone Metastasis In Vivo?
Pierrick G. Fournier et al.
NEOPLASIA (2010)
Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells
John Wen-Cheng Chang et al.
CANCER LETTERS (2009)
Zoledronate facilitates large-scale ex vivo expansion of functional gamma delta T cells from cancer patients for use in adoptive immunotherapy
M. Kondo et al.
CYTOTHERAPY (2008)
A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo
K. Sato et al.
BRITISH JOURNAL OF CANCER (2006)
Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression
Fernando Vidal-Vanaclocha et al.
CANCER AND METASTASIS REVIEWS (2006)
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice
B Ory et al.
CANCER (2005)
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors - A randomized, phase III, double-blind, placebo-controlled trial
LS Rosen et al.
CANCER (2004)
The distinct contributions of murine T cell receptor (TCR)γδ+ and TCRαβ+ T cells to different stages of chemically induced skin cancer
M Girardi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group
LS Rosen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
New aspects of natural-killer-cell surveillance and therapy of cancer
MJ Smyth et al.
NATURE REVIEWS CANCER (2002)
Targeting of tumor cells for human γδ T cells by nonpeptide antigens
Y Kato et al.
JOURNAL OF IMMUNOLOGY (2001)
Regulation of cutaneous malignancy by γδ T cells
M Girardi et al.
SCIENCE (2001)
Vγ2Vδ2 T-cell receptor-mediated recognition of aminobisphosphonates
H Das et al.
BLOOD (2001)
分享论文
